Goldfarb H A
Department of OB/GYN, Mountainside Hospital, Montclair, NJ 07042, USA.
JSLS. 1999 Oct-Dec;3(4):253-60.
This study compares results of endometrial ablation alone and in combination with myoma coagulation. Subsequent surgery rates were 38% for ablation alone and 12% for combined therapy.
The purpose of this study was to compare hysterectomy rates following various surgical procedures to treat profuse uterine bleeding as well as myomatous uteri.
This is a descriptive study of women who underwent endometrial ablation alone, endometrial ablation with myoma coagulation, or endometrial resection with myoma coagulation to treat profuse uterine bleeding as well as myomatous uterus. From 1986 to 1995, the author performed 52 endometrial ablation procedures; 88 myoma coagulation and endometrial ablation procedures; and 28 myoma coagulations with resection of submucous myomas in patients who were subsequently available for follow-up. Patients were followed up for up to ten years.
Of the patients undergoing ablation alone, 20 (38%) of 52 required a second surgery for continued symptoms during a mean follow-up of 47 months. Five of these patients (9.6%) underwent hysterectomy. Of the patients who underwent endometrial ablation plus myoma coagulation (myolysis), 11 (12.5%) of 88 required a repeat surgical procedure during a mean follow-up of 25 months. Five of these patients (5.7%) underwent hysterectomy. Volumetric measurements revealed an average reduction in fibroid volume of 54.5% in this patient group following treatment with a gonadotropin-releasing hormone (GnRH) agonist and combined myoma coagulation and endometrial ablation surgery. Of the 28 patients who underwent myoma coagulation plus resection, five (18%) required a repeat procedure. Of these five, one (4%) required hysterectomy. Fibroid volume in this group was reduced by a mean of 72.6% following administration of a GnRH agonist and combined laparoscopic and hysteroscopic surgery as described. The rate of reoperation was significantly lower among patients receiving endometrial ablation with myoma lysis with or without resection compared with those undergoing endometrial ablation alone (P<0.01).
Myoma coagulation (myolysis), when combined with endometrial ablation among women with symptomatic fibroids and bleeding, reduces all subsequent surgery rates compared with endometrial ablation alone. Myolysis with endometrial resection also results in a reduced need for hysterectomy.
本研究比较了单纯子宫内膜消融术以及联合肌瘤凝固术的治疗结果。单纯消融术的后续手术率为38%,联合治疗的后续手术率为12%。
本研究的目的是比较各种手术治疗大量子宫出血以及子宫肌瘤后的子宫切除术发生率。
这是一项针对接受单纯子宫内膜消融术、子宫内膜消融联合肌瘤凝固术或子宫内膜切除术联合肌瘤凝固术以治疗大量子宫出血及子宫肌瘤的女性的描述性研究。1986年至1995年期间,作者实施了52例子宫内膜消融手术;88例肌瘤凝固及子宫内膜消融手术;以及28例对黏膜下肌瘤进行切除的肌瘤凝固术,这些患者随后可供随访。对患者进行了长达十年的随访。
在接受单纯消融术的患者中,52例中有20例(38%)在平均47个月的随访期间因症状持续而需要二次手术。其中5例患者(9.6%)接受了子宫切除术。在接受子宫内膜消融加肌瘤凝固术(肌瘤溶解术)的患者中,88例中有11例(12.5%)在平均25个月的随访期间需要再次手术。其中5例患者(5.7%)接受了子宫切除术。体积测量显示,该患者组在接受促性腺激素释放激素(GnRH)激动剂治疗以及联合肌瘤凝固术和子宫内膜消融手术后,肌瘤体积平均减少了54.5%。在接受肌瘤凝固加切除术的28例患者中,5例(18%)需要再次手术。在这5例患者中,1例(4%)需要子宫切除术。如所述,在给予GnRH激动剂并联合腹腔镜和宫腔镜手术后,该组肌瘤体积平均减少了72.6%。与单纯接受子宫内膜消融术的患者相比,接受有或无肌瘤切除的子宫内膜消融联合肌瘤溶解术的患者再次手术率显著更低(P<0.01)。
对于有症状的肌瘤和出血的女性,肌瘤凝固术(肌瘤溶解术)与子宫内膜消融术联合使用时,与单纯子宫内膜消融术相比,可降低所有后续手术率。肌瘤溶解术联合子宫内膜切除术也减少了子宫切除术的需求。